Comparison of the Quality of Life in Women with Breast Cancer Under Different Adjuvant Hormone Therapy Regimens: A Cross-Sectional Study
Open Access
- 1 August 2026
- journal article
- Published by InkVista Publishing House
- Vol. 19 (1) , 77-91
Abstract
Introduction: Adjuvant hormonal therapy (AHT) lowers recurrence in hormone receptor–positive breast cancer, but evidence comparing its impact on quality of life (QoL) across menopausal status is limited. This study aimed to compare QoL across different AHT regimens in premenopausal and postmenopausal women with breast cancer. Methods: In this cross-sectional study, ...Keywords
This publication has 25 references indexed in Scilit:
- Current and future burden of breast cancer: Global statistics for 2020 and 2040The Breast, 2022
- The Prevalence of Breast Cancer in Iranian Women: A Systematic Review and Meta-AnalysisIndian Journal of Gynecologic Oncology, 2022
- The impact of medication side effects on adherence and persistence to hormone therapy in breast cancer survivors: A qualitative systematic review and thematic synthesisThe Breast, 2021
- Factors influencing adherence to adjuvant endocrine therapy in breast cancer-treated women: using real-world data to inform a switch from acute to chronic disease managementBreast Cancer Research and Treatment, 2020
- An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients: EORTC QLQ-BR45Annals of Oncology, 2020
- Influence of adherence to adjuvant endocrine therapy on disease-free and overall survival: a population-based study in Catalonia, SpainBreast Cancer Research and Treatment, 2019
- Health-Related Quality of LifeSurgical Oncology Clinics of North America, 2018
- Longitudinal Effects of Adjuvant Endocrine Therapy on the Quality of Life of Post-menopausal Women with Non-metastatic ER+ Breast Cancer: A Systematic ReviewPharmacoEconomics - Open, 2018
- Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trialsThe Lancet Oncology, 2015
- Aromatase inhibitor therapy and hair loss among breast cancer survivorsBreast Cancer Research and Treatment, 2013